Table 1.
Baseline and 12-month values of serum VEGF-C and VEGF-D and plasma VEGF-C concentrations in the MILES trial
| Biomarker | Sirolimus Group |
Placebo Group |
||||
|---|---|---|---|---|---|---|
| Baseline [Median (95% CI)] | 12 mo [Median (95% CI)] | P Value | Baseline [Median (95% CI)] | 12 mo [Median (95% CI)] | P Value | |
| Serum VEGF-D, pg/ml | 1,345 (924–2,006) | 709 (508–1,010) | <0.0001 | 1,329 (722–1,735) | 1,231 (734–2,546) | 0.30 |
| Serum VEGF-C, pg/ml | 6,860 (6,600–8,198) | 5,453 (4,804–6,248) | <0.0001 | 7,028 (6,337–7,490) | 6,752 (5,814–7,622) | 0.08 |
| Plasma VEGF-C, pg/ml | 268 (231–367) | 204 (147–266) | 0.03 | 217 (177–313) | 238 (157–303) | 0.14 |
Definition of abbreviations: CI = confidence interval; MILES = Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus; VEGF-C = vascular endothelial growth factor C; VEGF-D = vascular endothelial growth factor D.